Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus delbrueckii + lactobacillus fermentum
- Development stage
- Unknown
- Lead developer
- Mayoly Spindler
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Vaginal
01
Overview
**Lactobacillus delbrueckii + lactobacillus fermentum** is an oral probiotic or postbiotic antidiarrheal combination composed of two Lactobacillus strains commonly referred to together as **Lactobacillus LB** and marketed as **Lacteol Fort**. It has been used primarily for diarrhea-related gastrointestinal disorders and has also been studied in irritable bowel syndrome with diarrhea predominance. Its proposed activity is not a single receptor-target interaction but a microbiome-directed effect that includes antagonism of enteric pathogens, protection of the intestinal epithelial surface, restoration of microbial balance, and local immunomodulatory effects in the gut. Public sources verify the exact combination in clinical research and marketed-product contexts, including ClinicalTrials.gov records for IBS-D and branded Lactéol product pages describing Lactobacillus LB as the active digestive postbiotic ingredient.
- Brand names
- Lacteol FortLactéol Fort
- Other names
- Lactobacillus LBLBlactobacillus delbrueckii + lactobacillus fermentum
Beyond the preview
Go deeper on lactobacillus delbrueckii + lactobacillus fermentum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus delbrueckii + lactobacillus fermentum.